Fukuhara H, Irabu Y, Kakazu T, Nakamura H, Shigeno Y, Saito A, Owan T, Oshiro H, Miyaguni T, Nakasone K
First Department of Internal Medicine, Faculty of Medicine, University of the Ryukyus.
Jpn J Antibiot. 1993 Jan;46(1):53-9.
Cefpodoxime (CPDX-PR) was evaluated clinically in respiratory tract infections. The results obtained are summarized as follows; 1. The total number of the patients who were treated with CPDX-PR was 61, out of whom 53 cases were evaluated for clinical efficacy and 55 cases were investigated for the safety of the drug. CPDX-PR was given orally twice a day at 100-200 mg for 5-21 days. 2. Clinical efficacies were excellent in 9 patients, good in 36, fair in 4 and poor in 4. The overall clinical efficacy was 84.9%. In particular, CPDX-PR showed satisfactory efficacy for acute respiratory infections and mild chronic respiratory infections, with efficacy rates of 88.6% (31/35) and 100% (8/8), respectively. 3. No adverse reactions was observed, but slight and transient elevation of BUN was noted. In conclusion, it has been confirmed that CPDX-PR is an excellent and safe drug for the treatment of the respiratory tract infections.
头孢泊肟酯（CPDX-PR）针对呼吸道感染进行了临床评估。获得的结果总结如下：1. 接受CPDX-PR治疗的患者总数为61例，其中53例评估了临床疗效，55例调查了药物安全性。CPDX-PR每日口服两次，剂量为100-200毫克，疗程为5-21天。2. 临床疗效为优的有9例，良的有36例，中（尚可）的有4例，差的有4例。总体临床有效率为84.9%。特别是，CPDX-PR对急性呼吸道感染和轻度慢性呼吸道感染显示出满意的疗效，有效率分别为88.6%（31/35）和100%（8/8）。3. 未观察到不良反应，但注意到血尿素氮有轻微短暂升高。总之，已证实CPDX-PR是治疗呼吸道感染的一种优良且安全的药物。
